Novo Nordisk A/S's stock has taken a hit as its semaglutide-based therapies – Ozempic for diabetes and Wegovy for obesity – surprisingly missed consensus in the second quarter but the Danish drugmaker is emphasising the significant volume growth and demand for the products which is not going to dry up anytime soon.
Sales of the company's GLP-1-based treatments may have come in considerably lower than analysts’ estimates but they are still flying off the shelf. Ozempic contributed DKK28.88bn ($4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?